With the aim of strengthening its pipeline of drugs targeting cancer, inflammation and other conditions, Inspyr Therapeutics has agreed to acquire Lewis and Clark Pharmaceuticals.

Following the all-stock transaction, the target company’s shareholders will own 50% of the acquirer company’s common shares.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The acquirer company is a clinical-stage biotechnology company, whereas the target company is a biotechnology company.

"Nippon Suisan Kaisha’s subsidiary Nissui Pharmaceutical has reached an agreement to its pharmaceutical subsidiary company based in Yamanashi, Japan, to Senshukai."

Both companies involved in the transaction are based in the US.

Nippon Suisan Kaisha’s subsidiary Nissui Pharmaceutical has reached an agreement to its pharmaceutical subsidiary company based in Yamanashi, Japan, to Senshukai.

Also based in Japan, the acquirer company is engaged in mail-order business.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now